SynthesisClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2024
Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.
Synthesis in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07335445 (Enhancing Screening Practices for Barrett's Esophagus), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhancing Screening Practices for Barrett's Esophagus
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Association of gastroesophageal reflux disease with the incidence of multiple cancers: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- The prevalence of Barrett 's esophagus in Iranian patients with gastrointestinal symptoms: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- E-cigarette use and Barrett's esophagus: evaluating a new risk in the era of vaping.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Evaluating ChatGPT-5 for Detection of Barrett's Esophagus and Grading of Esophagitis: A Multiclass Endoscopic Image Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- High Rates of Dysplasia in a Population-Based Analysis of "Incidental" Barrett's Esophagus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Article
- Assessing the Relationship Between Steatotic Liver Disease and Barrett's Esophagus: A Cross-Sectional Analysis of 5507 Screening Participants.Zeitschrift fur Gastroenterologie · 2026Article
- Optimal cannabinoid-terpene combination ratios suppress mutagenicity of gastric reflux in normal and metaplastic esophageal cells.World journal of gastroenterology · 2026Article
- Acid bile salt induces esophageal mucosal barrier dysfunction through miR-146a-5p-KYNU pathway in gastroesophageal reflux disease.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- The Impact of Hiatus Hernia Size on Dysplasia Progression in Patients With Barrett's Esophagus.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Risk factors for barrett's esophagus identified in a large-scale Japanese community cohort study.Scientific reports · 2026Article
- Endoscopic spectrum of autoimmune gastritis across disease stages: a focus on Barrett's esophagus and ME-NBI features.Frontiers in immunology · 2026Article
- A machine-learning model for staging autoimmune gastritis based on endoscopic and serological features.Frontiers in immunology · 2026Article
- Etiology and Pathophysiology of Barrett's Esophagus/Neoplasia.Digestion · 2026Review
- Endoscopic Screening of Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- Barrett High-Grade Dysplasia and Early Esophageal Adenocarcinoma in Patients With Positive Results on a Nonendoscopic Methylated DNA Biomarker Test.Gastroenterology & hepatology · 2025Article
- Sponge cytology combined with endoscopy in patients with long-segment Barrett's esophagus: A retrospective case series and literature review.The Journal of international medical research · 2025Review
- Prevalence of Barrett's esophagus and gastroesophageal reflux disease 5 years after laparoscopic sleeve gastrectomy: A retrospective study.World journal of gastrointestinal surgery · 2025Article
- Global Hypomethylation as Minimal Residual Disease (MRD) Biomarker in Esophageal and Esophagogastric Junction Adenocarcinoma.Cancers · 2025Article
- Multidimensional Assessment of Psychiatric Adverse Events Related to Proton Pump Inhibitors: A Real-World, Pharmacovigilance Study.CNS neuroscience & therapeutics · 2025Article
- Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett Esophagus Through Methylated DNA Biomarker Triage.Gastroenterology & hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsAlthough gastroesophageal reflux disease (GERD) symptoms are an essential criterion for Barrett's esophagus (BE) screening in most gastroenterology society guidelines, a significant proportion of BE and esophageal adenocarcinoma (EAC) cases do not endorse them. In a systematic review and meta-analysis, we aimed to study the prevalence of BE/EAC in those with and without GERD.
methodsA systematic search was conducted through 5 major databases for studies reporting prevalence of BE/EAC in patients with and without GERD. Pooled proportions and odds ratios (ORs) of BE, long-segment BE, short-segment BE, dysplasia, and EAC in patients with and without GERD were synthesized.
resultsForty-three articles (12,883 patients with GERD; 51,350 patients without GERD) were included in the final analysis. BE prevalence was 7% (95% confidence interval [CI], 5.8%-8.5%) and 2.2% (95% CI, 1.6%-3%) among individuals with and without GERD, respectively. EAC prevalence was 0.6% (95% CI, 0.4%-1%) and 0.1% (95% CI, 0%-0.2%) in those with and without GERD, respectively. The overall risks for BE (OR, 2.91; 95% CI, 2.06-4.11) and long-segment BE (OR,4.17; 95% CI, 1.78-9.77) were higher in patients with GERD, but the risk for short-segment BE (OR, 1.77; 95% CI, 0.89-3.52) did not differ between the two groups. In 9 population-based high-quality studies (2244 patients with GERD; 3724 patients without GERD), BE prevalence in patients without GERD was 4.9% (95% CI, 2.6%-9%). BE prevalence was highest in North American studies (10.6% [GERD] and 4.8% [non-GERD]).
conclusionsBE prevalence in those without GERD is substantial, particularly in large high-quality population-based studies. These data are important to factor in future BE/EAC early detection guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.